Retraction of: “Effect of Timolol on Optineurin Aggregation in Transformed Induced Pluripotent Stem Cells Derived From Patient With Familial Glaucoma” by Satoshi Inagaki, Kazuhide Kawase, Michinori Funato, Junko Seki, Chizuru Kawase, Kazuki Ohuchi, Tsubasa Kameyama, Shiori Ando, Arisu Sato, Wataru Morozumi, Shinsuke Nakamura, Masamitsu Shimazawa, Daisuke Iejima, Takeshi Iwata, Tetsuya Yamamoto, Hideo Kaneko and Hideaki Hara (
Invest Ophthalmol Vis Sci. 2018;59(6):2293–2304),
https://doi.org/10.1167/iovs.17-22975.
After publication of our article, “Effect of Timolol on Optineurin Aggregation in Transformed Induced Pluripotent Stem Cells Derived From Patient With Familial Glaucoma,” we became aware that blood samples were collected after obtaining informed consent from the patients but without receiving ethical approval from the ethics committee at the institute where they were collected. On the other hand, the ethical approvals were obtained at the other institutes where the induced pluripotent stem cells (iPS) was generated and experiments were conducted.
Because of these wrong ethical procedures, we wish to retract this article and apologize for the confusion.